* PAVmed Inc PAVM.OQ PAVM.O is expected to show a fall
in
quarterly revenue when it reports results on May 10
(estimated).
* The New York City-based company is expected to report a
24.0% decrease in revenue to $228 thousand from $300 thousand a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for PAVmed Inc is for a
loss
of 24 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for PAVmed Inc
is
$1.5, above its last closing price of $0.49.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.27 -0.26 -0.29 Missed -9.4
Jun. 30 2022 -0.23 -0.23 -0.29 Missed -26.1
Mar. 31 2022 -0.19 -0.19 -0.20 Missed -2.6
Dec. 31 2021 -0.14 -0.15 -0.20 Missed -33.3
Sep. -0.14 -0.13 -0.15 Missed -15.4
30 2021
Jun. 30 2021 -0.10 -0.10 -0.14 Missed -43.6
Mar. 31 2021 -0.12 -0.12 -0.13 Missed -8.3
Dec. 31 2020 -0.11 -0.11 -0.17 Missed -50
This summary was machine generated May 9 at 02:04 GMT. All
figures in US dollars unless otherwise stated